Summary of Product Characteristics

1. Name of the Medicinal Product.

Instabact Ointment 2%

2. Qualitative and Quantitative Information.

Each gram of ointment contains 20mg of mupirocin (2% w/w mupirocin)

For the full list of excipients, see section 6.1

3. Pharmaceutical Form

White to off-white semi solid ointment.

4. Clinical Particulars

4.1. Therapeutic Indications

Mupirocin is indicated in adults and children.

Mupirocin is a topical antibacterial agent, active against those organisms responsible for the majority of skin infection, e.g. Staphylococcus aurous, including methicillin-resistant strains, other staphylococci, and streptococci. It is also active against Gram-negative organisms such as Escherichia coli and hemophilic influenzae. Mupirocin Ointment issued for skin infections, e.g. impetigo, folliculitis, and furunculosis

4.2. Posology and method of administration

Posology:

Adults (including elderly) and Paediatric population:

Mupirocin Ointment should be applied to the affected area up to three times a day for up to 10 days.

The area may be covered with a dressing or occluded if desired.

Method of administration:

Topical.

Do not mix with other preparations as there is a risk of dilution, resulting in a reduction of the antibacterial activity and potential loss of stability of the mupirocin in the ointment

4.3. Contraindications

Hypersensitivity to the active substance or to any of the Excipients listed in 6.1.

This Mupirocin Ointment is not suitable for ophthalmic or intranasal use

4.4. Special warnings and Precautions for Use

Should a possible sensitization reaction or severe local irritation occur with the use of Mupirocin Ointment, treatment should be discontinued, the product should be washed off and appropriate therapy instituted.

As with other antibacterial products, prolonged use may result in over growth of non-susceptible organism. Pseudo membranous colitis has been reported with the use of antibiotics and may range in severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in patients who develop diarrhea during or after antibiotic use. Although this is less likely to occur with topically applied mupirocin, if prolonged or significant diarrhea occurs or the patient experiences abdominal cramps, treatment should be discontinued immediately and the patient investigated further.

Renal Impairment

Polyethylene glycol can be absorbed from open wounds and damaged skin and is excreted by the kidneys. In common with other poly ethylene glycol-based ointments, Mupirocin Ointment should not be used in conditions where absorption of large quantities of poly ethylene glycol is possible, especially if there is evidence of moderate or severe renal impairment. Mupirocin Ointment is not suitable for:

-Ophthalmic use;

-intranasal use (in neon atesor infants);

-use in conjunction with cannulae;

-at the site of central venous cannulation.

Avoid contact with the eyes. If contaminated, the yes should be thoroughly irrigated with water until the ointment residues have been removed.

4.5. Interaction with other medicinal products and other forms of Interaction.

No interaction studies have been performed

4.6. Fertility, Pregnancy and breastfeeding.

Pregnancy:

Reproduction studies on mupirocin in animals have been revealed no evidence of harm to the foetus. As there is no clinical experience on its during Pregnancy,Mupirocin ointment should only be used in pregnancy when the potential benefit outweigh the possible risk of treatment.

Breast-feeding:

It is unknown when the mupirocin is excreted in human fertility. Studies in rats showed no effects on fertility.

Fertility:

There are no data on the effects of mupirocin on human fertility. Studies in rats showed no effects on fertility

4.7. Effects on ability to drive and use machines

Mupirocin 2%w/w Ointment has nor eligible influence on the ability to drive and use machines

4.8. Undesirable effects

Adverse reactions are listed below by system organ class and frequency. Frequency enciesare defined as very common (1>10), common (1/100 to <1/10),uncommon (1/1000 ≥ to <1/100), rare 1/10,000to<1/1,000),very rare(<1/10,000),including isolated reports . Common and Uncommon adverse reactions were determined from pooled safety data from a clinical trial population 1573 treated patients encomposing12 clinical studies. Very nare adverse reactions are primarily determined post –marketing experience data and therefore refer to reporting rate rather than true frequency.

System organ class	Frequency	Undesirable effects
Immune System Disorder	Very rare	Systemic allergic reactions including anaphylaxis, generalized rash,urti caria and angio hadbenn reported with Mupirocin Ointment.
Skin and Subcutaneous tissue Disorder System	Common Uncommon	Burning localized to the area of application Itching, erythema, stinging and dryness localized to the area of application. Cutaneous Sensitiation

Reporting of Suspected Adverse Reactions:

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Pharmacy and Poisons Board, Pharmacovigilance Electronic Reporting System (PvERS) https://pv.pharmacyboardkenya.org

4.9. Overdose

Symptoms
There is currently limited experience with overdosage of mupirocin.

Management
The toxicity of mupirocin is very low. In the event of accidental ingestion of the ointment, symptomatic treatment should be given.
In case of erroneous oral intake of large quantities of the ointment, renal function should be closely monitored in patients with renal insufficiency because of the possible side effects of polyethylene glycol.
There is no specific treatment for an overdose of mupirocin. In the event of overdose, the patient should be treated supportively with appropriate monitoring as necessary.
Further management should be as clinically indicated or as recommended by the national poisons centre, where available

5. Pharmacological Properties

5.1. Pharmacodynamic Properties

Pharmacotherapeutic group: Antibiotics and chemotherapeutics for topical use, ATC code: D06AX09

Mechanism of action

Mupirocin is a novel antibiotic produced through fermentation by Pseudomonas fluorescens. Mupirocin inhibits isoleucyl transfer-RNA synthetase, thereby arresting bacterial protein synthesis. Mupirocin has bacteriostatic properties at minimum inhibitory concentrations and bactericidal properties at the higher concentrations reached when applied locally.

Mechanism of Resistance

Low-level resistance in staphylococci is thought to result from point mutations within the usual staphylococcal chromosomal gene (ileS) for the target isoleucyl tRNA synthetase enzyme. High-level resistance in staphylococci has been shown to be due to a distinct, plasmid encoded isoleucyl tRNA synthetase enzyme.

Intrinsic resistance in Gram negative organisms such as the Enterobacteriaceae could be due to poor penetration of the outer membrane of the Gram-negative bacterial cell wall.

Due to its particular mode of action, and its unique chemical structure, mupirocin does not show any cross-resistance with other clinically available antibiotics.

Microbiological Susceptibility

The prevalence of acquired resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infection is questionable.

Commonly susceptible species
*Staphylococcus aureus**
*Streptococcus pyogenes**
Streptococcus spp.(β-haemolytic,otherthan*S.pyogenes*)
Species for which acquired resistance may be a problem
Staphylococcus spp.,coagulase negative
Inherently resistant organisms
Corynebacterium spp.

Micrococcu sspp.

5.2. Pharmacokinetic Properties

After topical application of Mupirocin Ointment, mupirocin is only very minimally absorbed systemically and that which is absorbed is rapidly metabolised to the antimicrobially inactive metabolite, monic acid. Penetration of mupirocin into the deeper epidermal and dermal layers of the skin is enhanced in traumatised skin and under occlusive dressings.

Elderly:
No restrictions unless there is evidence of moderate or severe renal impairment (see section 4.4).

5.3. Preclinical safety data

Pre-clinical effects were seen only at exposures which are extremely unlikely to cause concern for humans under normal conditions of use. Mutagenicity studies revealed no risks to man

6. Pharmaceutical Particulars

6.1. List of Excipients

Polyethylene Glycol 400

Polyethylene Glycol 4000

6.2. Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products

6.3. Shelf-life

24 months.

6.4. Special Precautions for Storage

Store at a temperature not exceeding 30°C.

6.5. Nature and contents of container

Available in 15gm and 50gm laminated tube internally coated with an epoxy non-toxic resin closed with polyethylene screw caps in a carton along with pack insert.

6.6. Special precautions for disposal and other handling

Not Applicable.

7. Marketing Authorization Holder

Cachet Pharmaceuticals Private Limited
Address: 415, Shah Nahar Ind. Estate,

Dr. E. Moses Road, Worli,

Mumbai-400 018

Maharashtra, India

Manufactured by:
Curetech Skincare

Plot No. 32,33 & 34, Phase –IV, Bhatoli Kalan, Baddi, Distt. Solan, (H.P.) 173205 India

8. Marketing Authorization Number

H2024/CTD10529/22739

9. Date of First Authorization

9th February 2024

10. Date of Revision of the text

November 2024